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Abstract
Background: Retinoids regulate key developmental pathways throughout life, and have potential uses for differentiation
therapy. It should be possible to identify novel retinoids by coupling new chemical reactions with screens using the
zebrafish embryonic model.
Principal Findings: We synthesized novel retinoid analogues and derivatives by amide coupling, obtaining 80–92% yields. A
small library of these compounds was screened for bioactivity in living zebrafish embryos. We found that several structurally
related compounds significantly affect development. Distinct phenotypes are generated depending on time of exposure,
and we characterize one compound (BT10) that produces specific cardiovascular defects when added 1 day post
fertilization. When compared to retinoic acid (ATRA), BT10 shows similar but not identical changes in the expression pattern
of embryonic genes that are known targets of the retinoid pathway. Reporter assays determined that BT10 interacts with all
three RAR receptor sub-types, but has no activity for RXR receptors, at all concentrations tested.
Conclusions: Our screen has identified a novel retinoid with specificity for retinoid receptors. This lead compound may be
useful for manipulating components of retinoid signaling networks, and may be further derivatized for enhanced activity.
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Introduction
Chemical genetics is an approach for identifying small molecules
that alter the function of biological pathways, resulting in the
induction or rescue of a specific phenotype [1,2,3,4]. Forward
chemical genetics involves screening a library of compounds to find
small molecules that generate a consistent phenotype in a biological
assay, analogous to more traditional genetic screens. An advantage
of chemical genetics over traditional genetics is the inherent
conditional effect, and if it relates to human disease, a small
molecule may serve as a starting point for drug discovery. The
ability to modulate function specifically and rapidly makes small
molecules especially useful tools for studying processes like
development in which the timing of protein function is critical.
Currently, systematic methods for identifying small molecules that
alter specific developmental processes are limited, so the number of
useful small molecule developmental probes remains small.
However, using combinatorial techniques, it is possible to rapidly
screen a large number of small molecules and identify those that
induce a novel phenotype in a cellular or embryonic system [5].
Here we describe a chemical genetic approach by interfacing a
library of small molecules with developing embryos. Specifically, we
are interested in characterizing new compounds that interact with
developmentally important receptor-mediated pathways, acting as
antagonist oragonist,inordertomanipulatesignalingpathwaysand
to identify new gene targets of these pathways. For this purpose we
have synthesized retinoic acid analogues and derivatives and tested
their bioactivity in the context of developing zebrafish embryos.
The zebrafish is a vertebrate with tissues and organ systems that
develop and are organized similarly to humans, at the anatomical,
physiological and molecular levels, thereby facilitating the study of
biological processes and the development of human disease models
that are inaccessible or limited using invertebrate model organisms
[6]. Several hundred synchronously developing embryos can be
obtained from mating a single pair of adults. The embryos develop
externally and it is feasible to screen large numbers of compounds
in a high-throughput manner [7]. Finally, the zebrafish embryo is
transparent. Therefore, internal organs and structures can be
visualized in the intact, living organism, facilitating multiple or
continuous observations of dynamic processes.
Retinoic acid (RA), a member of the retinoid family of lipids
and mediator of vitamin A activity, is an essential morphogen in
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the development of a number of organ systems including retina,
brain, heart, the urogenital system, and lungs are dependent on
RA. The developmental defects resulting from vitamin A
deficiency as well as the teratogenic effects of retinoid overdose
are well documented [9]. Due to its effect on cell differentiation
and proliferation, RA is now being used as a therapeutic tool in
dermatology and oncology [10]. For example, RA provides a
paradigm for differentiation therapy, an approach to treat
malignant cells that are blocked for differentiation, so that they
overcome the block and resume the process of differentiation into
mature cells., However, apart from success in differentiation
therapy for acute promyelocytic leukemia, retinoid therapies have
not translated well to other cancers. While isotretinoin, a 13-cis-
retinoic acid, has been widely used for a range of dermatological
conditions, it also has severe teratogenic effects including
craniofacial, cardiovascular, thymic and central nervous system
malformations [11]. Therefore, the identification of retinoids with
novel bioactivity is of clinical relevance [12]. The most important
mechanism of RA activity is the regulation of gene expression.
This is accomplished by its binding to nuclear retinoid receptors
that are ligand-activated transcription factors [13]. Thus, RA acts
as a transcriptional activator for a large number of other
downstream regulatory molecules, including enzymes, transcrip-
tion factors, cytokines, and cytokine receptors. Although the
overwhelming majority of experimental studies have focused on
RA receptor–dependent mechanisms, there have been indications
of other, non-classical modes of action. This might occur through
ligand interactions with enzymes such as protein kinase C, by
direct activation of electrical synapses, or from interaction with
putative cell surface receptors [14]. Toward a long-term goal of
identifying new antagonists and agonists that target specific
pathways, we focused on retinoid signaling, since it plays key
roles in patterning the body axis, in the formation of many organs,
and in maintaining tissue homeostasis.
Results
Derivation of a library of retinoid analogues
We first synthesized retinoic acid analogues of amides (retinoids)
by coupling RA with amine derivatives (Fig. 1). First, retinoic acid
was converted to retinoyl chloride, then in the presence of DMF,
base, and aniline derivatives, we synthesized the corresponding 4-
hydroxy phenyl amine derivatives (1, 2, 3, 4, 10, 11, 14, 15, 17, 18.
19, 20, 21 and 22). This procedure gave 80–90% yield. To develop
efficacy and potency we synthesized novel retinoic acid analogue 8
[15] and then further derivatized to corresponding amide
derivatives (5, 6, 7, 9, 12, 13 and 16) by amide coupling reactions.
Figure 1. Strategy to synthesize novel retinoids. See text and Methods for details.
doi:10.1371/journal.pone.0010004.g001
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generate a small library of these retinoid derivatives (Fig. 2) to
screen for bioactivity in zebrafish embryos.
A developmental screen for analogue activity
After synthesis and purification of the compounds, they were
screened for bioactivity using the zebrafish model. For this purpose,
fertilized eggs were obtained from paired adults and cultured until 3–
5 hours post-fertilization (hpf). Embryos were then grouped into
individual wells of a 12 wellplate, each well containing 3–10 embryos
in 1 ml of 1X E3 buffer, 1% DMSO, and 1 mM Tris pH 7.5. Each
test compound was diluted inDMSO to 10 mMstocks,and added to
the cultured embryos at a final concentration of 10 mM. Treated
embryos were cultured until 24 hpf and assessed for morphological
alterationscomparedtoembryostreated withvehicle(DMSO)alone.
In several independent experiments the effect of compounds was
consistent and penetrant. Several of the compounds (10, 11, and 20)
cause similar and very significant disruptions of the body axis (not
shown). Dilutions of these three compounds were compared to
evaluate their relative dose-response activities, and compound 10 was
found to be most active, since it altered body axis formation when
added at a concentration as low as 312 nM, a concentration at which
the other two compounds are not active. We designated this lead
compound BT10 and characterized its activity in more detail.
As shown in Fig. 3A, when BT10 is added to embryos at 5 hpf
there is by 24 hpf a severe truncation of the body axis, although the
embryo survives and forms a simple mass of pigmented tissue on the
remaining yolk by 48 hpf (Fig. 3B). We do not believe that the effect
is toxic, because the embryos are alive (even moving or ’’twitching‘‘,
and continuing to develop pigmentation), although the ’’poster-
Figure 2. Compounds tested for activity altering normal zebrafish development. Note that compounds 10, 11, and 20 were found to
generate similar phenotypes, while compound 10 (red) was chosen for further study, since it had highest activity based on a dose response study. For
simplicity, highly related compounds are grouped on the right.
doi:10.1371/journal.pone.0010004.g002
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compoundisdelayeduntil8hpf,thereisnowasignificantincreasein
development of the trunk, although head structures are largely
undefined and the tail is much shorter than in control embryos at 24
hpf(Fig.3C)or48hpf(Fig.3D).Theseembryonic’’posteriorization‘‘
phenotypes are consistent and similar to defects caused by addition
of RA [16,17] and known RAR activators, such as DTAB [18].
Exposure to BT10 after 24 hpf disrupts cardiovascular
development
A major advantage of using small molecules for manipulating
pathways is that the activity can be tightly controlled, simply by
the timing of delivery. We next sought to determine if BT10
remains active and is able to disrupt later stages of development.
For this purpose, embryos were cultured with BT10 (or control
vehicle) added at 24 hpf, and phenotypes were evaluated at 60 hpf.
In multiple, independent experiments, BT10-treated embryos
display a consistent and penetrant phenotype (n.50), comprising
a characteristic malformation of the ventral yolk structure and
disruption of normal heart tube development (Fig. 4). While the
embryos show a minor posterior tail defect, the body trunk and
gross head/brain structure are relatively normal. However, the
heart tube that forms is thin, non-looping, and very weakly
beating. This phenotype is also consistent with those reported for
Figure 3. BT10 added during early embryogenesis causes a major disruption of the body axis. Shown are representative embryos (from
3 experiments, for each sample n=20) treated with BT10 at 10 mM (A-D) compared to embryos treated only with vehicle (DMSO) as control. BT10 was
added at 5 hpf (A, B) or 8 hpf (C, D). DMSO alone was added at 5 hpf (E, F). Embryos were allowed to develop until 24 hpf (A, C, E) or 48 hpf (B, D, F).
The position of the yolk is indicated in panels A and B. All embryos are viewed laterally, anterior to the right, dorsal at the top.
doi:10.1371/journal.pone.0010004.g003
Figure 4. BT10 causes specific cardiovascular defects when added at 24 hpf. Shown are representative embryos (from 3 experiments, for
each sample n=20) that were cultured between 24–60 hpf in the presence of DMSO alone (A, control) or BT10 (B). Note the defined morphological
structure of the ventral yolk sac (arrow). A normal looping heart tube fails to develop in these embryos. Panels C and D show higher magnification
views of representative control (C) and BT10-treated (D) embryos, respectively. The red block arrow indicates blood flowing through the normal
control heart, which is not evident in the BT10-treated embryos. Views are lateral, anterior to the right, dorsal at the top.
doi:10.1371/journal.pone.0010004.g004
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aldh1a2 gene [17].
Previous studies showed that excess RA eliminates or sharply
reduces the amount of cardiac tissue in Xenopus [19] or zebrafish
[20] embryos. More recent studies confirmed that heart tissue is
severely diminished in zebrafish embryos treated with RA at a
relatively high concentration (0.3 mM). At a relatively lower
concentration (0.1 mM), ventricular tissue is preferentially sensitive
to RA compared to atrial tissue [21]. Therefore, we next
compared the effects of adding BT10 and RA during embryo-
genesis on cardiac development. For this purpose we compared
the effect of RA at concentrations of BT10 that generates grossly
similar body axis defects (low: 5 mM BT10, 0.1 mM ATRA; high:
15 mM BT10, 0.3 mM ATRA). We used quantitative RT-PCR
(qPCR) to evaluate the effect of a pan-cardiomyocyte marker
(cmlc2) in addition to markers specific to ventricular cardiomy-
coytes (vmhc) and atrial cardiomyocytes (ahmc). As shown in Fig. 5A,
when assayed at 24 hpf, both compounds severely diminish
expression levels of cardiac markers when added at 5 hpf. Notably,
similar to ATRA, embryos treated with BT10 retain detectable
(albeit substantially decreased) levels of the atrial marker, under
conditions that eliminate detectable expression of the ventricular
marker. When added at 24 hpf, the expression levels for these
cardiac markers are much less disturbed (Fig. 5B), consistent with a
morphogenetic defect rather than a failure to develop cardiomy-
ocytes.
We therefore evaluated more closely the phenotype of disrupted
heart tube development when similar concentrations of ATRA or
BT10 are added later in embryogenesis. For this purpose we
exposed embryos derived from transgenic fish carrying a cmlc2:gfp
reporter, which facilitates visualization of heart tube formation
and subsequent cardiac looping (Fig. 6). At these concentrations,
heart tube formation occurs normally, and both atrial and
ventricular chambers are readily apparent at 48 hpf. However,
at 48 hpf the heart remains relatively linear compared to the
control vehicle-treated embryos and fails to undergo proper
looping morphogenesis. This looping defect likely contributes to
the cardiac edema that develops by 60 hpf. Therefore both early
and late effects of BT10 on cardiogenesis are consistent with RA-
pathway-dependent defects in cell specification or heart tube
looping, respectively.
BT10 is an agonist for retinoid signaling
In order to test directly if BT10 affects retinoid signaling, we
analyzed the expression of specific known downstream targets of
the pathway when the compound was added to cultured
embryos, compared with ATRA or control (DMSO). For this
purpose we again used concentrations of the compounds that
gave grossly similar body axis defects (5 mM BT10, 0.1 mM
ATRA). As shown in Fig. 7, BT10 and ATRA affect target gene
expression levels with similar trends, measured by qPCR,
consistent for specific activation of the retinoid pathway. For
example, both BT10 and ATRA strongly activate expression of
cyp26a1 (a known downstream target that participates in negative
feedback), while addition of either leads to significant decreases
for genes that are repressed by excessive retinoids, aldh1a2, pax2a,
and egr2b (krox20).
The specificity of action of BT10 was confirmed by evaluating
the spatial expression pattern for retinoid target genes using in situ
hybridization. As shown in Fig. 8, compared to control, egr2b
expression in hindbrain segments rhombomere 3 and 5 is
eliminated by BT10. Likewise, transcripts for pax2a in anterior
structures including the midbrain-hindbrain boundary, optic
stalk, and otic vesicle, in addition to the ventral pronephric ducts,
is largely eliminated. Reduction in the expression domains of myod
and ntl are much more subtle, but consistent with a loss of dorso-
anterior mesoderm. The expression domain for cyp26a1 is
expanded throughout the embryo, compared to DMSO-treated
embryos in which it is restricted to the posterior tailbud region.
BT10 exposure causes a more extensive expansion of this marker
compared to ATRA (although note that BT10 is used in this
experiment at a much higher concentration compared to ATRA,
which is overall more active). Therefore, as suggested by the
qPCR data, BT10 appears to function by a mechanism similar
but perhaps not identical to ATRA. Both compounds cause
similar concentration-dependent changes in marker expression
patterns.
BT10 activity is specific to RAR and not RXR sub-types
Finally, we performed experiments to test directly if BT10
functions by interaction with retinoid receptors, and we compared
its specificity for receptor interaction with ATRA. Retinoids signal
through two families of receptors, RAR and RXR, and there are
three distinct genes that encode receptors for each family (a, b,
and c). We used a cell culture assay to express receptors and probe
the specificity of ligand-receptor interaction [18]. In this assay, the
three RARs are fused to the Gal4 DNA-binding domain, and co-
transfected with a Gal4-dependent luciferase reporter, and the
Figure 5. BT10, similar to RA, inhibits cardiomyocyte differen-
tiation when added early during embryogenesis. (A) Embryos
were cultured starting at 5 hpf in the presence of vehicle alone (DMSO,
control), or ‘‘low’’ (0.1 mM, 5.0 mM) or ‘‘high’’ (0.3 mM, 15 mM)
concentrations of ATRA or BT10, respectively. RNA was harvested at
24 hpf and used to measure by qPCR relative transcript levels, as
indicated. All cardiac markers are significantly reduced in transcript
levels by ATRA or BT10, and for both compounds, the ventricular
marker is relatively more sensitive. (B) Embryos were treated in the
same manner starting at 24 hfp, and RNA was harvested at 48 hpf.
Under these conditions there was not a consistent significant inhibition
of cardiomyocyte differentiation, based on levels of the same cardiac
markers. These data are from one representative experiment, showing
the mean relative transcript levels (normalized to the control) of
triplicate qPCR assays, using 30 embryos per sample.
doi:10.1371/journal.pone.0010004.g005
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transfected with an RA-responsive luciferase reporter. As shown in
Fig. 9, ATRA can interact with all 6 receptors, leading to strong
activation of the luciferase reporters with a concentration-
dependent response. In contrast, BT10 can activate each of the
RAR receptors 10–40 fold, but the compound is inactive with
respect to RXR activation, at the concentrations tested. Overall,
the ability of BT10 to activate the RAR receptors is significantly
reduced compared to ATRA, based on the dose response.
Activities of the reporters are entirely dependent on co-expressed
receptors. Since BT10 has a significantly lower activity for RARs
compared to ATRA, we considered that BT10 might have low
activity for RXRs, not detected under these conditions. However,
even using a 10-fold higher concentration (100 mM) BT10 fails to
activate the RXR receptors (Fig. 10). Above this concentration,
BT10 is not tolerated by the cultured cells. Therefore, the
compound is completely inert with respect to RXR activation, at
all concentrations we were able to test. Therefore, BT10 shows
interaction with a restricted class of retinoid receptors and appears
to target RARs with specificity.
Discussion
We synthesized a small library of retinoic acid analogues and
tested their activity by evaluating phenotypic changes caused in
developing zebrafish embryos. Several of the compounds had
Figure 6. BT10 added at 24 hpf causes a defect in heart tube looping, similar to excess RA. Shown are representative embryos (n=30)
containing a cmlc2:gfp transgene were cultured in vehicle alone (control) or in the presence of ATRA or BT10 at the concentrations indicated, and as
described in Fig. 3B, beginning at 24 hpf. They were then photographed at 48 hpf in both brightfield and fluorescence, and the images overlayed to
document the morphology of the heart tube (green). In control embryos the ventricle (V) is fully looped relative to the atrium (A), indicated by the
dotted white line. In contrast, embryos cultured in the presence of ATRA or BT10 develop a relatively linear heart tube (at ‘‘low’’ or ‘‘high’’
concentrations), which is the major obvious morphological abnormality.
doi:10.1371/journal.pone.0010004.g006
Figure 7. Shown are qPCR results for the markers as indicated, using embryos that were taken at various developmental stages,
also indicated. Transcript levels are calculated relative to those from vehicle (DMSO) treated embryos (light blue), for embryos treated with 0.1 mM
ATRA (medium blue) or 5 mM BT10 (dark blue). The three markers in the left panel are repressed by both compounds, while cyp26a (right panel) is
activated. The asterisks indicate statistically significant differences compared to control (p,0.05), based on a Student’s T-test.
doi:10.1371/journal.pone.0010004.g007
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BT10 at concentrations as low as 300 nM. It is interesting to point
out the structural similarities and distinctions of the three most
active compounds. For compounds 10 and 11 a hydroxyl group is
not directly attached to the phenyl ring system but is flanked by
mono-methyl (compound 10) or ethyl (compound 11) groups,
whereas in compound 20 the phenyl group contains two hydroxyl
groups meta to each other. Therefore, it appears that either more
hydroxyl groups in the phenyl ring system or a hydroxyl group
away from the phenyl ring system makes these retinoids active. It
would seem that the three compounds have the same or
overlapping targets, since the phenotypes they invoke are
essentially indistinguishable according to dose response experi-
ments. However, BT10 appears to have the highest affinity (or at
least activity), since it can affect axis development at the lowest
concentration. It remains possible that BT10 has enhanced
ADME (absorption, distribution, metabolism, or elimination)
properties compared to the other compounds. In addition to
activity during early embryogenesis, there are targets (the same or
different) that continue to be relevant to organ development at
later stages, and we documented specific defects in cardiovascular
morphology induced between 24–48 hpf. The loss of cardiac tissue
when BT10 is added early is likely due to loss of cardiac progenitor
tissue, as seen with excess RA. The cardiac morphology defect
when BT10 is added at later stages may be indirect, for example
due to abnormalities in the vascular or hematopoietic systems.
Further studies will be required to understand this phenotype, but
it is also seen similarly with excess RA.
Due to the success of differentiation therapy using retinoids to
target the PML-RARa oncogene that causes acute promyelocytic
leukemia, there has been much interest in the development of
retinoids for cancer and metabolic disease therapies. However,
retinoids are also teratogens, and there may be significant benefit
obtained using ligands with defined and limited receptor specificity
(reviewed in [12]). The active target of retinoids is a heterodimer
composed of both RAR and RXR receptors. While RAR only
interacts with RXR, the RXRs form functional complexes with a
variety of additional nuclear receptors. Therefore, pan-agonists
may have considerable off-pathway activation (or repression) that
might be undesirable or teratogenic. For this purpose, the
identification of compounds that are specific to receptor sub-types
provide interesting leads of better-defined agonists for differenti-
ation therapy. The gene expression analysis shows that BT10 does
affect known targets of ATRA, although there is not a complete
concordance with the sensitivity for target gene changes. Based on
the morphology dose response study, ATRA is more active than
BT10. While BT10 shows stronger effects in the qPCR assays
shown here, the relative differences in gene induction or repression
may reflect both the different concentrations of the compounds
used in the assay, but also receptor complex specificity. This may
reflect differential affinity of BT10, showing specificity for RAR
and not RXR sub-types. Our results show the utility of combining
focused small molecule derivation, applied to a biological screen
using the zebrafish model, to identify new compounds with desired
target activity and specificity.
Materials and Methods
Generation of compounds
All-trans retinoic acid (ATRA) was purchased from Sigma
Chemical Co. (Sigma-Aldrich). The dry DMF was stored over 4-A ˚
sieves and degassed before use by bubbling nitrogen through it for
at least 1 h. The other reagents and solvents were purchased from
commercial sources (Aldrich or Fisher) and used without further
purification. All reactions were conducted under a N2 atmosphere.
The reactions were monitored using TLC (Whatman PE SIL G/
UV Fluorescence UV254). All the products prepared were purified
by flash column chromatography on silica gel grade 62 (60–200
mesh, 150 A ˚). Proton nuclear magnetic resonance (
1H-NMR)
spectra were recorded in CDCl3 using a Bruker 300 MHz
instrument. Electrospray Ionization (ESI) mass spectra were
determined on a Thermo Finnigan LCQ Classic ion trap mass
spectrometer (Waltham, MA) in positive ionization mode.
Experimental detail of lead compound BT10:
(2E,4E,6E,8E)-[3,7-Dimethyl-9-(2,6,6-trimethyl-1-
cyclohexenyl)-nona-2,4,6,8-tetraenoylamino]-(4-
alcohol)phenylamide
A mixture of all-trans retinoic acid (ATRA) (100 mg,
0.33 mmol) in dry DMF (2 mL) and dry CH2Cl2 (2 mL) was
stirred under nitrogen atmosphere for 1 hr. Oxalyl chloride
Figure 8. Changes in the expression patterns for known
retinoid target genes confirm that BT10 is a retinoid agonist.
Shown are representative embryos (n=30) treated with vehicle (DMSO,
left panels), 0.1 mM ATRA (middle panels), or 5 mM BT10 (right panels)
and then analyzed by in situ hybridization at the 10 somite stage
(cyp26a), 75% epiboly (ntl), the 18 somite stage (myod and pax2a), or
the 26 somite stage (egr2b). Embryos are viewed laterally with anterior
to the right (egr2b, cyp26a), dorsally with anterior to the right (myod,
pax2a), or dorsally with animal pole to the top (ntl, arrows in both
panels). Note that in both ATRA and BT10 treated embryos, the normal
anterior expression domains are largely abolished (egr2b, arrows
indicate normal expression pattern marking the 3
rd and 5
th rhombo-
meres in the hindbrain of control embryos, and pax2a, arrow indicates
normal expression pattern in the midbrain-hindbrain boundary
domain), highly reduced (myod, disruption noted by arrow in BT10
panel), or more subtly inhibited (ntl, indicated by arrows in both
panels). In contrast, the expression domain of cyp26a is expanded in
BT10-treated embryos throughout the anterior region (arrow in BT10
panel).
doi:10.1371/journal.pone.0010004.g008
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red reaction mixture was stirred for another 1.5 h at room
temperature under nitrogen atmosphere. After carefully removing
the solvent, dry DMF was added (2 mL) immediately. At 0uC
under nitrogen atmosphere, Retinoyl chloride solution was added
dropwise to a solution of 4-aminobezyl alcohol (0.66 mmol,
81.28 mg) and triethylamine (1.00 mmol, 130 mL) in dry DMF
(2 mL). The dark-colored reaction mixture was stirred at room
temperature until TLC analysis indicated none remaining (about
2,3 h). The reaction was quenched with saturated NH4Cl and
extracted with ethyl acetate. The extracts were washed with H2O
and brine, then dried overage Na2SO4, and evaporated. The
residue was purified by flash column chromatography using
hexane/ethyl acetate (4/1) as the eluent to give BT10 as a yellow
solid. 1H-NMR (300 MHz, CDCl3): d 7.58 (d, J=6 Hz, 2H), 7.34
(d, J=8 Hz, 2H), 7.28 (s, 1H), 7.12–6.90 (m, 1H), 6.32–6.19 (m,
4H), 5.82 (s, 1H), 4.67 (s, 2H), 2.06–2.03 (b, 4H), 1.74 (s, 3H),
1.67–1.62 (m, 4H), 1.51–1.49 (m, 2H), and 1.05 (s, 6H).
13C NMR
(300 MHz,CDCl3): d166.1, 152.2, 139.3, 138.4, 137.8, 136.7,
131.8, 130.4, 129.3, 128.7, 127.3, 122.8, 120.5, 65.7, 40.1, 34.4,
33.3, 29.0, 22.7, 19.8,1 4.6 and 13.5. HRMS: (C27H35NO2) Calcd
([M+H
+]) 406.2746; found 406.2762.
Screening in zebrafish
For all experiments we used zebrafish that are a hybrid of AB and
TU strains. All animal research was conducted according to
national and international guidelines, with animals maintained and
embryos obtained according to standard fish husbandry protocols
Figure 9. BT10 is selective for RAR receptors. Shown are the results of reporter assays in which specific activated receptors mediate
luciferase reporter activity. Hek293T cells were transfected with the indicated RA receptor construct, in addition to the relevant reporter
luciferase plasmid, and a non-retinoid regulated renilla reporter plasmid to control for transfection and lysate recovery. Twenty-four hours following
transfection, cells were incubated with ATRA (blue diamonds) or BT10 (orange squares), at the doses indicated on the X axis (with the number (x)
representing 10
x M final concentration). Control transfections lacked the receptor expression construct (yellow triangles or green marked boxes, for
ATRA or BT10, respectively). Data is plotted relative to values obtained with transfected cells that were treated with DMSO, with that value set to 1.0,
not shown on the graphs. ATRA activates robustly all 6 receptors, while BT10 shows specificity to RARs and does not activate RXRs at all
concentrations tested.
doi:10.1371/journal.pone.0010004.g009
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Institutional Animal Care and Use Committee of Weill Cornell
Medical College, and all animals were maintained by trained and
approved Animal Institute staff of Weill Cornell Medical College.
Embryos were obtained at the one cell stage from paired adults, and
cultured in system water. For the initial screen we used embryos at 3
or 5 hpf. They were grouped into individual wells of a 12 well plate,
each well containing 3–10 embryos in 1 ml of 1X E3 buffer (5 mM
NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4), 1%
DMSO, and 1 mM Tris pH 7.5. Compounds were diluted in
DMSO to 10 mM stocks, and added to the cultured embryos to a
final concentration of 10 mM. Subsequent experiments used further
dilutions to determine dose response, and used later staged embryos
to define the temporal response.
Gene expression analysis
Whole-mount in situ hybridization was performed essentially as
described [23]. Hybridization was performed at 70uC, in 60%
formamide buffer with digoxigenin-labeled RNA antisense probes.
The probes used for in situ hybridization were prepared using
either Sp6 or T7 polymerase with linearized templates. Probes
were either as described [18], or were first isolated and subcloned
by RT-PCR using whole embryo RNA.
For cyp26a1, Forward primer: TE2261, TCCGAACTGCA-
GAAGTCCTC, reverse primer: TE2262, GCTTCCACCA-
GTTCTTGCTC, product size of 519 bp.
For egr2b, Forward primer: TE2265 GCCACTTCTCCAG-
CACTCTC, reverse primer: TE2266TCTGCGGAGTGTAA-
GCTGTG, product size of 408 bp.
For quantitative real-time PCR assays, RNA was extracted from
staged wildtype or morphant embryos using the RNeasy mini kit
(Qiagen). First-strand cDNA synthesis was performed using the
Superscript III First-Strand Synthesis System (Invitrogen). The
cDNA was analyzed with Qiagen QuantiTect SYBR Green Mix
(Qiagen) by quantitative RT–PCR using the Light Cycler 480II
(Roche). All samples were prepared in triplicate, and each
experiment was repeated at least 3 times using independent
batches of embryos. The PCR cycle conditions were 95uC for 15
minutes, (94uC for 15 seconds, 60uC for 30 seconds, and 72uC for
30 seconds) for 40 cycles. The Ct value data were analyzed using
the 2
2DDT method [24]. Primers used were:
aldh1a2, F: ACTGCCAGGAGAGGTGAAGA, R: CAGGG-
TTGTACGTGTGGAAG
pax2a, F: GTGTCAAGCGCTTCCAATG, R: CCAGAGC-
CATCTGAACCATC
egr2b, F: AACACTGCCAGCCTCTGTG, R: GCTTC-
TCCGTGCTCATATCC
cyp26a, F: TCCTGGAGGATTCAGAGTCG, R: ATCGTG-
CGTGTCACAGATG
Receptor specificity assays
Hek293T cells were grown in DMEM containing 10% fetal
bovineserum for24hr and 5610
4 cellsweretransfectedwith 200 ng
pCMX-Gal-L-hRAR, 50 ng tk-px3-luc, and 1 ng renilla luciferase
reporterplasmidor200 ngpCMX-mRXR,50 ngtk-apoA1-lucand
1 ng renilla plasmid, using Lipofetamine 2000, according to the
manufacturer’s protocol (Invitrogen). Control transfections lacking
receptors included only 50 ng tk-px3-luc or tk-apoA1-luc and 1 ng
renilla luciferase reporter plasmid. Twenty-four hours following
transfection, cells were treated with various concentrations (10
29 M
to 10
23 M) of ATRA or BT10 diluted into DMSO, or were treated
with DMSO alone. Cell lysates were collected 48 hr after
transfection and were assayed for luciferase activity using the
Dual-LuciferaseH Reporter Assay System (Promega). The luciferase
values were normalized to the renilla luciferase reporter, and results
furthernormalized tothevaluesobtainedincellstreated withvehicle
(DMSO) alone. The results were obtained from two independent
experiments in assays done each time in duplicate.
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Figure 10. BT10 is selective for RAR receptors even at super-pharmacologic concentrations. Since BT10 has lower apparent affinity to all
receptors compared to ATRA, the activity of BT10 was tested at 10 and 100 mM with each RXR isoform. Even at the highest concentration, there is no
activation of RXR-dependent reporters, in contrast to activation of the control RARa receptor.
doi:10.1371/journal.pone.0010004.g010
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